金河生物(002688) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥591,527,500.46, representing a 10.08% increase compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was ¥22,740,808.57, a significant increase of 65.92% year-over-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥17,597,872.51, up 48.13% from the previous year[2]. - The basic earnings per share for Q3 2024 was ¥0.0294, reflecting a 67.05% increase compared to the same quarter last year[2]. - Total operating revenue for Q3 2024 reached ¥1,657,273,697.64, an increase of 5.5% compared to ¥1,569,845,460.39 in the same period last year[28]. - The net profit for Q3 2024 was approximately ¥113.07 million, a slight decrease from ¥113.86 million in Q3 2023, representing a decline of about 0.7%[29]. - Operating profit for Q3 2024 increased to ¥125.34 million, compared to ¥119.12 million in the same period last year, marking an increase of approximately 5.5%[29]. - The company reported a total comprehensive income of ¥106.27 million for Q3 2024, down from ¥125.75 million in Q3 2023, a decrease of about 15.5%[30]. - Basic and diluted earnings per share for Q3 2024 were both ¥0.1461, an increase from ¥0.1321 in Q3 2023, representing a growth of approximately 22.6%[30]. Assets and Liabilities - The total assets at the end of Q3 2024 amounted to ¥5,737,889,958.39, an increase of 5.21% from the end of the previous year[2]. - The company's total assets reached ¥5,737,889,958.39, up from ¥5,453,807,416.04, indicating a growth of 5.2%[27]. - Current liabilities decreased to ¥1,878,369,713.89 from ¥2,257,325,331.09, a reduction of 16.7%[27]. - Long-term borrowings increased significantly to ¥958,577,124.01 from ¥497,490,378.32, representing an increase of 92.7%[27]. - The total liabilities of the company rose to ¥3,230,179,388.11, compared to ¥2,937,125,973.28, reflecting an increase of 10%[27]. - The total equity attributable to shareholders was ¥2,241,356,113.30, slightly down from ¥2,246,791,261.75, a decrease of 0.2%[27]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥379,581,732.41, showing a substantial increase of 122.90%[2]. - Net cash flow from operating activities increased by CNY 209,289,917.59, a growth of 122.90%, primarily driven by improved sales performance and better collection of receivables[14]. - Cash flow from investing activities decreased by CNY 215,661,444.85, a decline of 44.76%, mainly due to reduced payments for fixed assets and investments[15]. - Cash flow from financing activities increased by CNY 492,384,221.41, a growth of 39.23%, primarily due to increased debt repayments and other financing activities[17]. - The cash and cash equivalents at the end of Q3 2024 amounted to ¥725.03 million, up from ¥555.88 million at the end of Q3 2023, reflecting an increase of about 30.5%[32]. - The company incurred a total investment cash outflow of ¥266.18 million, a decrease from ¥481.84 million in Q3 2023, indicating a reduction of approximately 44.8%[32]. - The financing cash inflow for Q3 2024 was ¥1.85 billion, compared to ¥1.69 billion in Q3 2023, showing an increase of about 9.2%[32]. Expenses and Income - The company experienced a 127.31% increase in financial expenses, primarily due to increased bank borrowing and the capitalization of interest expenses[9]. - Income tax expenses increased by CNY 6,216,098.60, a growth of 126.11%, mainly due to the performance growth of subsidiaries[11]. - Other income increased by CNY 262,333.80, a growth of 414.42%, mainly due to deductions from risk deposits of contractors who failed to meet production targets[11]. - Research and development expenses increased to ¥56,656,746.61, compared to ¥45,876,398.38 in the previous year, marking a rise of 23.5%[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 30,819[18]. - The largest shareholder, Inner Mongolia Jinhe Holdings Co., Ltd., holds 31.33% of the shares, totaling 241,758,670 shares[18]. - The company has repurchased a total of 15,221,500 shares, accounting for 1.97% of the total share capital, with a total transaction amount of 50,098,780.21 RMB[24]. - The company plans to use self-raised funds to repurchase shares for employee stock ownership plans, with a total repurchase amount between 50 million and 100 million RMB[24]. Other Developments - The company approved the establishment of a research institute in collaboration with Chengdu Agricultural Technology Center on July 17, 2024[21]. - The company has implemented a stock option incentive plan, granting 11.75 million stock options at an exercise price of 2.94 RMB per option[22]. - The company recorded an investment loss of ¥631,039.01 from the disposal of its subsidiary, Animal Nutrition Company[10]. - Net loss from asset impairment increased by CNY 9,904,635.03, a growth of 133.23% compared to the same period last year, mainly due to the decline in market prices of certain veterinary chemical drugs and starch-related products, leading to inventory write-downs[11]. - Other comprehensive income after tax decreased by CNY 18,687,459.87, a decline of 157.13%, primarily due to exchange rate fluctuations affecting the foreign currency financial statements of overseas subsidiaries[12]. Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth[28].